Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 16/20 | 0.56 |
| ▸ | CCND1 | P24385 | 15/20 | 0.56 |
| ▸ | CDK1 | P06493 | 10/20 | 0.56 |
| ▸ | CDK4 | P11802 | 10/20 | 0.56 |
| ▸ | CCNE1 | P24864 | 7/20 | 0.46 |
| ▸ | CDK6 | Q00534 | 6/20 | 0.46 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5008008 | 0.92 | CDK2 (0.56) | CDK2CCND1CDK1CDK4CCNE1 | |
| SCHEMBL5049489 | 0.86 | CDK2 (0.49) | CDK2CCND1CDK1CDK4CCNE1 | |
| SCHEMBL5001905 | 0.82 | CDK1 (0.58) | CDK2CCND1CDK1CDK4CCNE1 | |
| SCHEMBL5001992 | 0.77 | CDK2 (0.51) | CDK2CCND1CDK1CDK4CCNE1 | |
| SCHEMBL5002093 | 0.75 | CDK2 (0.57) | CDK2CCND1CDK1CDK4CCNE1 | |
| SCHEMBL14124456 | 0.74 | CDK1 (0.46) | CDK2CCND1CDK1CDK4CDK6 | |
| SCHEMBL1517104 | 0.73 | CDK2 (0.53) | CDK2CCND1CDK1CDK4CCNE1 | |
| SCHEMBL5002370 | 0.72 | GBA1 (0.45) | — | |
| SCHEMBL5001638 | 0.72 | CDK2 (0.55) | CDK2CCND1CDK1CDK4CCNE1 | |
| SCHEMBL5005638 | 0.72 | IGF1R (0.48) | CDK2CCND1CDK1CDK4CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7405220-B2 | Pyrazolopyrimidines | HOFFMANN-LA ROCHE INC. (US) | 2008-07-29 | — | — | US | disclosed |
| EP-1758871-B1 | PYRAZOLO PYRIMIDINES | HOFFMANN LA ROCHE (CH) | 2007-11-14 | — | — | EP | disclosed |
| US-20050277655-A1 | e.g. [3-(2-Methoxy-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl]-phenyl-amine; cyclin-dependent kinase (Cdk1, 2, 4) inhibitor; anticarcinogenic agent; breast, lung, colon and prostate solid tumors | DING QINGJIE | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277655-A1 | e.g. [3-(2-Methoxy-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl]-phenyl-amine; cyclin-dependent kinase (Cdk1, 2, 4) inhibitor; anticarcinogenic agent; breast, lung, colon and prostate solid tumors | CDK1, CDK4, CDK2 | CDK2 3/4885CCND1 42/4885CDK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.